Case report: Consumption of psilocybin-containing mushrooms results in amelioration of OCD symptoms
Marijuana Stocks, Finance, & InvestingUncategorized April 9, 2021 MJ Shareholders
Approximately 2.3% of adults will suffer from symptoms of Obsessive-Compulsive Disorder at some point in their life. The disorder is characterized by intrusive, persistent thoughts and compulsive behaviors and a substantial number of people don’t respond well to standard treatments.
A report recently published in the Journal of Psychoactive Drugs presents the case of a 30-year-old man who showed clinically significant reductions in treatment-resistant OCD symptoms after consuming psilocybin-containing mushrooms, more commonly known as “magic” mushrooms.
The man had suffered from disabling symptoms even after treatment with a variety of medications, including antidepressants, nonsteroidal anti-inflammatory drugs, and ketamine. He was undergoing treatment at a clinic when he decided to take psychedelic mushrooms.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
